What is the recommended management for a 60-year-old female with Atypical Squamous Cells of Undetermined Significance (ASCUS) and a positive test for a non-high-risk Human Papillomavirus (HPV) strain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of ASCUS with Non-High-Risk HPV Positive in a 60-Year-Old Female

For a 60-year-old female with ASCUS and positive non-high-risk HPV, follow-up with repeat co-testing (Pap and HPV) in 3 years is recommended, and she should not exit screening at age 65 without additional negative tests. 1

Recommended Management Algorithm

Initial Assessment

  • ASCUS with HPV-positive (non-high-risk strain) in a 60-year-old woman represents a situation requiring careful follow-up due to increased risk compared to women with negative co-testing 1
  • The risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) in women with HPV-negative ASCUS is higher than with negative cytology alone, and this risk is even more concerning in women over 60 years of age 1

Follow-up Recommendations

  • Return for screening in 3 years with co-testing (Pap and HPV testing) 1
  • This 3-year interval recommendation is based on data from Kaiser Permanente Northern California (KPNC) showing that women with HPV-negative ASCUS have a higher risk than those with negative co-testing 1
  • For women with HPV-positive results (even non-high-risk types), closer monitoring is warranted due to increased risk of progression 2

Considerations for Exiting Screening

  • Women who reach age 65 with an HPV-positive ASCUS result should not exit screening 1
  • Continued surveillance is necessary until the patient has 2 consecutive negative co-tests or 3 consecutive negative Pap tests 1
  • KPNC data show that although dysplasia risk may be low after HPV-negative ASCUS in women over 60, cancer risk is disproportionately high 1

Evidence Strength and Considerations

  • The American Cancer Society (ACS) recommendation for 3-year follow-up is graded as "weak" due to limited data, but represents the most current consensus 1
  • This recommendation is based on analysis of approximately 1.1 million women from KPNC with extended follow-up 1
  • The principle of "equal management of equal risks" guides these recommendations - women with HPV-positive ASCUS have risk profiles requiring standardized follow-up 1

Special Considerations for Older Women

  • Women over 60 years with HPV-positive ASCUS may have a higher risk for cervical cancer during follow-up than women with negative co-test results 1
  • Risk estimates for cancer among women with HPV-positive ASCUS test results in this age group are based on limited data, but suggest caution is warranted 1
  • Approximately 0.5% to 1.0% of all women in their 60s will have an HPV-negative ASCUS result, and the risk is higher for HPV-positive results 1

Common Pitfalls to Avoid

  • Don't allow exit from screening at age 65 with a recent HPV-positive ASCUS result - this is insufficient for exiting screening 1
  • Don't extend screening interval beyond 3 years - the previous 5-year interval recommendation has been revised based on newer evidence 1
  • Don't assume non-high-risk HPV types are benign - while high-risk types pose greater risk, any HPV positivity warrants appropriate follow-up 2
  • Don't use HPV 16/18 genotyping to further assess women with ASCUS Pap test results, as this does not alter management in this context 1

References

Related Questions

What is the management for a 51-year-old patient with an Atypical Squamous Cells of Undetermined Significance (ASCUS) Pap smear result and high-risk Human Papillomavirus (HPV) E6/7 present?
What is the next step for a 58-year-old female with atypical squamous cells of undetermined significance (ASC-US) and a positive high-risk Human Papillomavirus (HPV) test?
What are the next steps for a 33-year-old female with a Papanicolaou (Pap) smear result showing Atypical Squamous Cells of Undetermined Significance (ASCUS) and positive for high-risk Human Papillomavirus (HPV) types, specifically E6/E7, with no prior history of abnormal Pap results?
What are the management and follow-up recommendations for a 47-year-old female with a diagnosis of atypical squamous cells of undetermined significance (ASC-US) and a negative Human Papillomavirus (HPV) Aptima test, along with other laboratory results?
What is the recommended management for an elderly female with Atypical Squamous Cells of Undetermined Significance (ASCUS) on Pap smear with Human Papillomavirus (HPV), genotype unknown?
What is the mode of transmission for pinworms (Enterobius vermicularis)?
Is Keflex (Cephalexin) a suitable alternative for treating a superficial wound infection with Schaublattia turicensis?
What is the diagnostic approach to Caustic Material Swallowing (CMS) and Caustic Esophageal Stricture (CES)?
What is the management and treatment for a patient with a Potts shunt?
Do Dilaudid (hydromorphone) and Tramadol cause memory impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.